Outcomes of treated human granulocytic ehrlichiosis cases

Emerg Infect Dis. 2002 Apr;8(4):398-401. doi: 10.3201/eid0804.010222.

Abstract

We conducted a case-control study in Wisconsin to determine whether some patients have long-term adverse health outcomes after antibiotic treatment for human granulocytic ehrlichiosis (HGE). A standardized health status questionnaire was administered to patients and controls matched by age group and sex. Consenting patients provided blood samples for serologic testing. Among the 85 previously treated patients, the median interval since onset of illness was 24 months. Compared with 102 controls, patients were more likely to report recurrent or continuous fevers, chills, fatigue, and sweats. Patients had lower health status scores than controls for bodily pain and health relative to 1 year earlier, but there was no significant difference in physical functioning, role limitations, general health, or vitality measures. The HGE antibody titer remained elevated in one patient; two had elevated aspartate aminotransferase levels. HGE may cause a postinfectious syndrome characterized by constitutional symptoms without functional disability or serologic evidence of persistent infection.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Case-Control Studies
  • Chronic Disease / therapy
  • Doxycycline / therapeutic use
  • Ehrlichia / isolation & purification
  • Ehrlichiosis / complications
  • Ehrlichiosis / drug therapy*
  • Follow-Up Studies
  • Health Surveys
  • Humans
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Doxycycline